DOCSLIB.ORG

Universidad De Oviedo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Universidad De Oviedo Universidad de Oviedo Programa de Doctorado “Investigación en Cáncer” “MOLECULAR MECHANISMS INVOLVED IN THE PATHOGENESIS OF HEAD AND NECK PARAGANGLIOMAS” TESIS DOCTORAL ANNA MERLO 23/06/2014 Universidad de Oviedo Programa de Doctorado “Investigación en Cáncer” “MOLECULAR MECHANISMS INVOLVED IN THE PATHOGENESIS OF HEAD AND NECK PARAGANGLIOMAS” TESIS DOCTORAL ANNA MERLO 23/06/2014 INDEX 1. INTRODUCTION…………………………………………………………………………………….2 1.1 The neural crest………………………………………………………………………………...2 1.2 The paraganglion system………………………………………………………………………3 1.2.1 The carotid body……………………………………………………………………….5 1.2.2 Adrenal medulla………………………………………………………………………..7 1.3 Paraganglioma and pheocromocitomas………………………………………………………7 1.4 Genetic background of HNPGLs and PGL/PCC…………………………………………….8 1.4.1 Von Hippel Lindau disease…………………………………………………………...9 1.4.2 Neurofibromatosis Type 1…………………………………………………………...10 1.4.3 Multiple Endocrine Neoplasia Type 2………………………………………………10 1.4.4 SDH mutation…………………………………………………………………………10 1.4.5 Trasmembran protein 127 (TMEM127)……………………………………………13 1.4.6 1.4.6. Myc-associated factor X (MAX)……………………………………………..13 1.4.7 Hypoxia inducible factor 2 alpha (HIF-2α)………………………………………....13 1.4.8 1.4.8. Fumarate Hydratase (FH)……………………………………………………14 1.4.9 1.4.9. Prolyl hydroxylase domain 2 and Kinesin family member 1B…………..14 1.5 Genetic testing…………………………………………………………………………………14 1.6 Hypoxia and tumorogenesis………………………………………………………………….15 2. OBJECTIVES……………………………………………………………………………………….18 3. MATERIALS AND METHODS…………………………………………………………………....19 3.1 Biological sample……………………………………………………………………………....20 3.2 Tumors and normal paraganglia samples…………………………………………………..20 3.3 Cell culture……………………………………………………………………………………...22 3.4 Chemical treatments…………………………………………………………………………..23 3.4.1 DMOG treatment………………………………………………………………………..23 3.4.2 TTFA treatment………………………………………………………………………….23 3.5 SiRNA treatment and transient transfection…………………………………………………24 3.6 In situ mutagenesis…………………………………………………………………………….25 3.7 Plasmid isolation……………………………………………………………………………….27 3.8 Bacterial culture medium…………………………………………………………………......27 3.9 DNA extraction…………………………………………………………………………………28 3.10 RNA extraction………………………………………………………………………………..29 3.11 cDNA synthesis……………………………………………………………………………….30 3.12 Real Time q-PCR with Syber Green® Master Mix (Life Technologies)………………...30 3.13 cDNA synthesis “RT-PCR TaqMan MicroRNA Assay Kit” (Applied Biosystem)………31 3.14 Real Time q-PCR with TaqMan 2X Universal PCR Master Mix…………………………32 3.15 Multiplex Ligation Probe-dependent Amplification………………………………………..32 3.16 Real time q-PCR method to confirm results from MLPA…………………………………35 3.17 Western blot…………………………………………………………………………………..36 3.18 Bisulfite Conversion and Pyrosequencing…………………………………………………36 3.18.1 Bisulfite Conversion…………………………………………………………………...37 3.18.2 Bisulfite Pyrosequenciation…………………………………………………………..37 3.19 Mutation analysis………………………………………………………………………………38 3.20 Polymerase Chain reaction (PCR)…………………………………………………………..38 3.21 Purification of PCR products…………………………………………………………………42 3.22 Immunocitochemestry………………………………………………………………………...42 3.23 Inmunofluorimetry …………………………………………………………………………….43 3.24 Immunohistochemestry……………………………………………………………………….43 3.25 Microarrays and TaqMan Low-Density Array (TLDA)……………………………………..44 3.26 Vascular Density………………………………………………………………………………44 3.27 Statistical Analysis…………………………………………………………………………….45 3.28 Microarray data analysis……………………………………………………………………...45 3.29 Bioinformatics Analysis of Oncomine Cancer Gene Microarray Database……………..45 4. RESULTS…………………………………………………………………………………………...47 4.1 Expression profiles analysis of HNPGLs vs normal samples……………………………..48 4.2 Validation of microarrays data………………………………………………………………..56 4.3 Relationship between the pseudohypoxic gene signatures of HNPGLs and the SDH mutation status……………………………………………………………………………………..57 4.4 C1-tumor analysis for somatic mutation in SDH……………………………………………58 4.5 Vascular density of C1-C2-HNPGLs and normal paraganglia……………………………58 4.6 Analysis of HIF-1α and HIF-2 α protein expression in HNPGL…………………………...59 4.7 Hypoxia related miR-210 is overexpressed in C1-HNPGL………………………………..60 4.8 Link between hypoxia/HIF-1α and ISCU and miR-210 expression………………………62 4.9 Identification of negative SDHB immunostaining in association with deregulation of HIF- 1α, miR-210, and ISCU……………………………………………………………………………65 4.10 Validation of the data on HIF-1α/miR-210/ISCU/SDHB pathway in HNPGLs…………68 4.11 Mecanisms of HIF-1α upregulation in non-SDHx HNPGLs………………………….......70 4.12 Somatic VHL mutations in HNPGLs in association with HIF-1α/miR-210 gene signature…………………………………………………………………………………………….72 4.13 Oncomine meta-analysis reveals similarities of pHx-HNPGL with ccRCC…………….77 4.14 VHL muation is involved in the activacion of the hypoxia signaling via HIF-1α……….80 4.15 pVHL loss of expression and VHL deletion do not activate HIF-1α/CAIX pathway in HNPGL………………………………………………………………………………………………81 4.16 HIF-1α is required for miR-210 over-expression…………………………………………82 4.17 VHL mutation F76del activates HIF-1α/CaIX/miR-210 pathway……………………….83 4.18 Loss of SDH does not activate the hypoxic pathway…………………………………….86 4.19 Analysis of VHL gene alteration in HNPGLs………………………………………………87 4.20 miRNA expression profiling of HNPGLs…………………………………………………...93 4.21 PGL2, PGL3 and PGL7 differ from the rest of HNPGLs in the expression of genes involved in differentiation and energetic metabolism…………………………………………..96 4.22 “Cluster reverse”……………………………………………………………………………...98 5. DISCUSSION……………………………………………………………………………………….100 5.1 Sporadic and SDH- HNPGLs show a common gene expression signature…………..101 5.2 Pseudohypoxic gene signature is driven by HIF-1α activation in a subgroup of HNPGLs…………………………………………………………………………………………..101 5.3 A robust and distinct pseudohypoxic HIF-1α-related miRNA profile defines a subset of sporadic HNPGLs………………………………………………………………………………..102 5.4 Comparison of the pseudohypoxia/hypoxia transcriptome common to all parasympathetic HNPGLs with that of sympathetic PGLs…………………………………..107 5.5 C1-HNPGLs share a common hypoxic profile with ccRCC……………………………..109 5.6 Identification of somatic VHL genes mutation in sporadic HNPGLs with psuedohypoxic gene expression profile………………………………………………………………………….110 5.7 Somatic VHL deletions are common in sporadic HNPGLs……………………………..113 5.8 VHL mutation p.F76del led to the activation of HIF1-α/CAIX/miR-210 pathway……..115 5.9 MAX muation analysis in HNPGLs………………………………………………………...115 5.10 miRNA expression profiling of HNPGLs…………………………………………………115 5.11 Part of the cluster mir-379/mir-656 is found downregulated in PGL2, PGL3 and PGL7………………………………………………………………………………………………116 5.12 miRNAs founded down-regulated in all NPGLs but not in PGL2, PGL3 and PGL7..119 6. CONCLUSIONES…………………………………………………………………………………..118 7. BIBLIOGRAPHY……………………………………………………………………………………120 8. SUPPLEMENTAL MATERIAL…………………………………………………………………….141 1. INTRODUCTION 1. INTRODUCTION Paragangliomas and pheocromocytomas are rare tumors arising from parasympathetic and sympathetic paraganglias through the body. Paraganglias are part of the autonomic nervous system that derives from embryonic neural crest. 1.1 The neural crest. The neural crest is an embryonic stem cell population unique to vertebrate that contribute to a wide variety of cells derivatives like sensory and autonomic ganglia of peripheral nervous system, adrenomedullary cells, cartilage and bone of the face, and pigmentation of the skin (1). During its formation, in the embryonic development, neural crest undergoes an extensive morphogenetic movement (Fig.1). Initially the cells that will form neural crest are located in the neural plate border, at the edges of the neural plate which is the embryonic region that will form the central nervous system. During the neurolation, the neural plate invaginates by elevation of the edge forming a cylindrical structure called neural tube which will later form the brain and spinal cord. The premigratory neural crest cells, during the process of neural tube closure, converge toward the midline and are located in the dorsal part of the neural tube. Then, they lose the intercellular connection and undergo an epithelial to mesenchymal transition (EMT), and acquire the ability to migrate and leave the neural tube (2, 3). 2 Figure 1. Neural crest formation. (A) Schematic diagram of transverse sections through embryo during neurulation. Cells that will form neural crest are located in the neural plate border (green), a territory between the neural plate and the non-neural ectoderm. (B) The neural plate invaginates, resulting in the elevation of the neural folds, which contain neural crest precursors. (C) After neural tube closure, neural crest cells lose intercellular connections and undergo an epithelial to mesenchymal transition and adcquire the capacity of migrate. (Image taken from reference 1). Neural crest cells emigrate and populate different niches throughout the embryo giving rise to different cell types and contribute to the formation of a variety of tissues and organs. 1.2 The paraganglion system. Some of the neural crest cells migrate beyond the pre-vertebral and para-vertebral parasympathetic chains or beyond the sympathetic chains and take on glandular character resulting in the paraganglion system. Paraganlia are dispersedly diffuse from 3 the middle ear and the skull base to the pelvic floor and are classified as either sympathetic or parasypathetic (4). Sympathetic paraganglia are located along the prevertebral and paravertebral sympathetic
Load more

Recommended publications
  • Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)
    This is a repository copy of Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/10846/ Article: Cox, L.E., Ferraiuolo, L., Goodall, E.F. et al. (13 more authors) (2010) Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). Plos One, 5 (3). Art no.e9872. ISSN 1932-6203 https://doi.org/10.1371/journal.pone.0009872 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS) Laura E. Cox1, Laura Ferraiuolo1, Emily F. Goodall1, Paul R. Heath1, Adrian Higginbottom1, Heather Mortiboys1, Hannah C. Hollinger1, Judith A. Hartley1, Alice Brockington1, Christine E.
    [Show full text]
  • The Switch from Fermentation to Respiration in Saccharomyces Cerevisiae Is Regulated by the Ert1 Transcriptional Activator/Repressor
    INVESTIGATION The Switch from Fermentation to Respiration in Saccharomyces cerevisiae Is Regulated by the Ert1 Transcriptional Activator/Repressor Najla Gasmi,* Pierre-Etienne Jacques,† Natalia Klimova,† Xiao Guo,§ Alessandra Ricciardi,§ François Robert,†,** and Bernard Turcotte*,‡,§,1 ‡Department of Medicine, *Department of Biochemistry, and §Department of Microbiology and Immunology, McGill University Health Centre, McGill University, Montreal, QC, Canada H3A 1A1, †Institut de recherches cliniques de Montréal, Montréal, QC, Canada H2W 1R7, and **Département de Médecine, Faculté de Médecine, Université de Montréal, QC, Canada H3C 3J7 ABSTRACT In the yeast Saccharomyces cerevisiae, fermentation is the major pathway for energy production, even under aerobic conditions. However, when glucose becomes scarce, ethanol produced during fermentation is used as a carbon source, requiring a shift to respiration. This adaptation results in massive reprogramming of gene expression. Increased expression of genes for gluconeogenesis and the glyoxylate cycle is observed upon a shift to ethanol and, conversely, expression of some fermentation genes is reduced. The zinc cluster proteins Cat8, Sip4, and Rds2, as well as Adr1, have been shown to mediate this reprogramming of gene expression. In this study, we have characterized the gene YBR239C encoding a putative zinc cluster protein and it was named ERT1 (ethanol regulated transcription factor 1). ChIP-chip analysis showed that Ert1 binds to a limited number of targets in the presence of glucose. The strongest enrichment was observed at the promoter of PCK1 encoding an important gluconeogenic enzyme. With ethanol as the carbon source, enrichment was observed with many additional genes involved in gluconeogenesis and mitochondrial function. Use of lacZ reporters and quantitative RT-PCR analyses demonstrated that Ert1 regulates expression of its target genes in a manner that is highly redundant with other regulators of gluconeogenesis.
    [Show full text]
  • Plexin A4 (PLXNA4) (NM 181775) Human Tagged ORF Clone Lentiviral Particle Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC206375L2V Plexin A4 (PLXNA4) (NM_181775) Human Tagged ORF Clone Lentiviral Particle Product data: Product Type: Lentiviral Particles Product Name: Plexin A4 (PLXNA4) (NM_181775) Human Tagged ORF Clone Lentiviral Particle Symbol: PLXNA4 Synonyms: FAYV2820; PLEXA4; PLXNA4A; PLXNA4B; PRO34003 Vector: pLenti-C-mGFP (PS100071) ACCN: NM_181775 ORF Size: 1566 bp ORF Nucleotide The ORF insert of this clone is exactly the same as(RC206375). Sequence: OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_181775.2, NP_861440.1 RefSeq Size: 2020 bp RefSeq ORF: 1569 bp Locus ID: 91584 UniProt ID: Q9HCM2 Protein Families: Druggable Genome MW: 58.1 kDa This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Plexin A4 (PLXNA4) (NM_181775) Human Tagged ORF Clone Lentiviral Particle – RC206375L2V Gene Summary: Coreceptor for SEMA3A.
    [Show full text]
  • Itraq-BASED QUANTITATIVE ANALYSIS of HIPPOCAMPAL POSTSYNAPTIC DENSITY-ASSOCIATED PROTEINS in a RAT CHRONIC MILD STRESS MODEL of DEPRESSION
    Neuroscience 298 (2015) 220–292 iTRAQ-BASED QUANTITATIVE ANALYSIS OF HIPPOCAMPAL POSTSYNAPTIC DENSITY-ASSOCIATED PROTEINS IN A RAT CHRONIC MILD STRESS MODEL OF DEPRESSION X. HAN, a,b,c W. SHAO, a,b,c Z. LIU, a,b,c S. FAN, a,b,c displayed differences in the abundance of several types of J. YU, b,c J. CHEN, b,c R. QIAO, b,c J. ZHOU b,c* AND proteins. A detailed protein functional analysis pointed to a,b,c,d P. XIE * a role for PSD-associated proteins involved in signaling a Department of Neurology, The First Affiliated Hospital, and regulatory functions. Within the PSD, the N-methyl-D-as- Chongqing Medical University, Chongqing, China partate (NMDA) receptor subunit NR2A and its downstream targets contribute to CMS susceptibility. Further analysis b Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China of disease relevance indicated that the PSD contains a com- c plex set of proteins of known relevance to mental illnesses Chongqing Key Laboratory of Neurobiology, Chongqing, China including depression. In sum, these findings provide novel d Department of Neurology, Yongchuan Hospital, Chongqing insights into the contribution of PSD-associated proteins Medical University, Chongqing, China to stress susceptibility and further advance our understand- ing of the role of hippocampal synaptic plasticity in MDD. Ó 2015 IBRO. Published by Elsevier Ltd. All rights reserved. Abstract—Major depressive disorder (MDD) is a prevalent psychiatric mood illness and a major cause of disability and suicide worldwide. However, the underlying pathophys- iology of MDD remains poorly understood due to its hetero- Key words: major depressive disorder, chronic mild stress, genic nature.
    [Show full text]
  • The Interactome of KRAB Zinc Finger Proteins Reveals the Evolutionary History of Their Functional Diversification
    Resource The interactome of KRAB zinc finger proteins reveals the evolutionary history of their functional diversification Pierre-Yves Helleboid1,†, Moritz Heusel2,†, Julien Duc1, Cécile Piot1, Christian W Thorball1, Andrea Coluccio1, Julien Pontis1, Michaël Imbeault1, Priscilla Turelli1, Ruedi Aebersold2,3,* & Didier Trono1,** Abstract years ago (MYA) (Imbeault et al, 2017). Their products harbor an N-terminal KRAB (Kru¨ppel-associated box) domain related to that of Krüppel-associated box (KRAB)-containing zinc finger proteins Meisetz (a.k.a. PRDM9), a protein that originated prior to the diver- (KZFPs) are encoded in the hundreds by the genomes of higher gence of chordates and echinoderms, and a C-terminal array of zinc vertebrates, and many act with the heterochromatin-inducing fingers (ZNF) with sequence-specific DNA-binding potential (Urru- KAP1 as repressors of transposable elements (TEs) during early tia, 2003; Birtle & Ponting, 2006; Imbeault et al, 2017). KZFP genes embryogenesis. Yet, their widespread expression in adult tissues multiplied by gene and segment duplication to count today more and enrichment at other genetic loci indicate additional roles. than 350 and 700 representatives in the human and mouse Here, we characterized the protein interactome of 101 of the ~350 genomes, respectively (Urrutia, 2003; Kauzlaric et al, 2017). A human KZFPs. Consistent with their targeting of TEs, most KZFPs majority of human KZFPs including all primate-restricted family conserved up to placental mammals essentially recruit KAP1 and members target sequences derived from TEs, that is, DNA trans- associated effectors. In contrast, a subset of more ancient KZFPs posons, ERVs (endogenous retroviruses), LINEs, SINEs (long and rather interacts with factors related to functions such as genome short interspersed nuclear elements, respectively), or SVAs (SINE- architecture or RNA processing.
    [Show full text]
  • Plexin A4 (PLXNA4) (NM 181775) Human Recombinant Protein – TP761981 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP761981 Plexin A4 (PLXNA4) (NM_181775) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Purified recombinant protein of Human plexin A4 (PLXNA4), transcript variant 2,full length, with N-terminal GST and C-terminal His tag, expressed in E. coli, 50ug Species: Human Expression Host: E. coli Tag: N-GST and C-His Predicted MW: 86 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25mM Tris, pH8.0, 150 mM NaCl, 10% glycerol,1% Sarkosyl. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_861440 Locus ID: 91584 UniProt ID: Q9HCM2 RefSeq Size: 2020 Cytogenetics: 7q32.3 RefSeq ORF: 1566 Synonyms: FAYV2820; PLEXA4; PLXNA4A; PLXNA4B; PRO34003 Summary: Coreceptor for SEMA3A. Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance in the developing nervous system. Class 3 semaphorins bind to a complex composed of a neuropilin and a plexin. The plexin modulates the affinity of the complex for specific semaphorins, and its cytoplasmic domain is required for the activation of down-stream signaling events in the cytoplasm (By similarity).[UniProtKB/Swiss-Prot Function] Protein Families: Druggable Genome This product is to be used for laboratory only.
    [Show full text]
  • A Negative Feedback Loop of the TOR Signaling Moderates Growth And
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.06.284745; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A negative feedback loop of the TOR signaling moderates 2 growth and enables rapid sensing of stress signals in plants 3 Muhammed Jamsheer K1#*<, Sunita Jindal1#>, Mohan Sharma1, Manvi Sharma1, Sreejath Sivaj2, 4 Chanchal Thomas Mannully1^, Ashverya Laxmi1* 5 1National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi 110067, India 6 2Department of Mechanical Engineering, Indian Institute of Technology Delhi, New Delhi, 110016, 7 India 8 9 <Current affiliation: Amity Food & Agriculture Foundation, Amity University Uttar Pradesh, Sector 10 125, Noida 201313, India 11 ^Current affiliation: Cell Metabolism Laboratory, School of Pharmacy, The Hebrew University of 12 Jerusalem, Jerusalem, 9112102, Israel 13 >Current affiliation: Department of Molecular Biology and Radiology, Mendel University in Brno, 14 Brno, 613 00, Czech Republic 15 16 #Equal first authors 17 18 *Corresponding authors 19 Ashverya Laxmi 20 Muhammed Jamsheer K 21 Email: AL: [email protected] (Lead Contact); MJK: [email protected] 22 ORCID: Ashverya Laxmi (0000-0002-3430-4200); Muhammed Jamsheer K (0000-0002-2135- 23 8760) 24 25 26 27 28 29 30 31 32 33 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.06.284745; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved.
    [Show full text]
  • © 2014 Jonathan Guo-Han Mun
    © 2014 Jonathan Guo-Han Mun HYPOGLYCEMIA-INDUCED CHANGES IN GLUCOSE METABOLISM IN THE HYPOTHALAMUS BY JONATHAN GUO-HAN MUN DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Nutritional Sciences in the Graduate College of the University of Illinois at Urbana-Champaign, 2014 Urbana, Illinois Doctoral Committee: Professor Rodney W. Johnson, Chair Professor J. Lee Beverly, Director of Research Associate Professor Justin S. Rhodes Associate Professor Manabu T. Nakamura ABSTRACT Hypoglycemia is the most common acute complication associated with insulin-dependent diabetes mellitus (Type 1 and advanced Type 2), which affects 300,000-500,000 individuals of all ages in the United States, with 30,000 new cases each year (1). It is characterized by low blood glucose concentration (less than 70 mg/dL or 4 mM) that can be attributed to a mismatch of insulin, food intake, sleep, and physical activity and can result in serious morbidity or death (2). The glucose counterregulatory response is the primary defense against hypoglycemia and involves (A) secretion of epinephrine and glucagon to elevate blood glucose concentration and (B) sympathetic activation to prompt the individual to take action against hypoglycemia through symptoms that include hunger, shaking, rapid heart rate, and sweating (2). Recurrent episodes of hypoglycemia result in failure of the counterregulatory response, which increases the frequency and severity of subsequent hypoglycemia. The underlying physiology by which this occurs is not well understood (3), but changes occurring in the ventromedial hypothalamus (VMH), a brain region that is responsible for initiating the counterregulatory response to hypoglycemia (4) is the most promising target.
    [Show full text]
  • Supplemental Table 3 Site ID Intron Poly(A) Site Type NM/KG Inum
    Supplemental Table 3 Site ID Intron Poly(A) site Type NM/KG Inum Region Gene ID Gene Symbol Gene Annotation Hs.120277.1.10 chr3:170997234:170996860 170996950 b NM_153353 7 CDS 151827 LRRC34 leucine rich repeat containing 34 Hs.134470.1.27 chr17:53059664:53084458 53065543 b NM_138962 10 CDS 124540 MSI2 musashi homolog 2 (Drosophila) Hs.162889.1.18 chr14:80367239:80329208 80366262 b NM_152446 12 CDS 145508 C14orf145 chromosome 14 open reading frame 145 Hs.187898.1.27 chr22:28403623:28415294 28404458 b NM_181832 16 3UTR 4771 NF2 neurofibromin 2 (bilateral acoustic neuroma) Hs.228320.1.6 chr10:115527009:115530350 115527470 b BC036365 5 CDS 79949 C10orf81 chromosome 10 open reading frame 81 Hs.266308.1.2 chr11:117279579:117278191 117278967 b NM_032046 12 CDS 84000 TMPRSS13 transmembrane protease, serine 13 Hs.266308.1.4 chr11:117284536:117281662 117283722 b NM_032046 9 CDS 84000 TMPRSS13 transmembrane protease, serine 13 Hs.2689.1.4 chr10:53492398:53563605 53492622 b NM_006258 7 CDS 5592 PRKG1 protein kinase, cGMP-dependent, type I Hs.280781.1.6 chr18:64715646:64829150 64715837 b NM_024781 4 CDS 79839 C18orf14 chromosome 18 open reading frame 14 Hs.305985.2.25 chr12:8983686:8984438 8983942 b BX640639 17 3UTR NA NA NA Hs.312098.1.36 chr1:151843991:151844258 151844232 b NM_003815 15 CDS 8751 ADAM15 a disintegrin and metalloproteinase domain 15 (metargidin) Hs.314338.1.11 chr21:39490293:39481214 39487623 b NM_018963 41 CDS 54014 BRWD1 bromodomain and WD repeat domain containing 1 Hs.33368.1.3 chr15:92685158:92689361 92688314 b NM_018349 6 CDS 55784 MCTP2 multiple C2-domains with two transmembrane regions 2 Hs.346736.1.21 chr2:99270738:99281614 99272414 b AK126402 10 3UTR 51263 MRPL30 mitochondrial ribosomal protein L30 Hs.445061.1.19 chr16:69322898:69290216 69322712 b NM_018052 14 CDS 55697 VAC14 Vac14 homolog (S.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Transcriptomic Regulation of Alternative Phenotypic Trajectories in Embryos of the Annual Killifish Austrofundulus Limnaeus
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses Fall 11-30-2017 Transcriptomic Regulation of Alternative Phenotypic Trajectories in Embryos of the Annual Killifish Austrofundulus limnaeus Amie L. Romney Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons, and the Genetics and Genomics Commons Let us know how access to this document benefits ou.y Recommended Citation Romney, Amie L., "Transcriptomic Regulation of Alternative Phenotypic Trajectories in Embryos of the Annual Killifish Austrofundulus limnaeus" (2017). Dissertations and Theses. Paper 4033. https://doi.org/10.15760/etd.5917 This Dissertation is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. Transcriptomic Regulation of Alternative Phenotypic Trajectories in embryos of the Annual Killifish Austrofundulus limnaeus by Amie Lynn Thomas Romney A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biology Dissertation Committee Jason Podrabsky, Chair Suzanne Estes Bradley Buckley Todd Rosenstiel Dirk Iwata-Reuyl Portland State University 2017 © 2017 Amie Lynn Thomas Romney ABSTRACT The Annual Killifish, Austrofundulus limnaeus, survives the seasonal drying of their pond habitat in the form of embryos entering diapause midway through development. The diapause trajectory is one of two developmental phenotypes. Alternatively, individuals can “escape” entry into diapause and develop continuously until hatching. The alternative phenotypes of A. limnaeus are a form of developmental plasticity that provides this species with a physiological adaption for surviving stressful environments.
    [Show full text]
  • Supplementary Table 3 Gene Microarray Analysis: PRL+E2 Vs
    Supplementary Table 3 Gene microarray analysis: PRL+E2 vs. control ID1 Field1 ID Symbol Name M Fold P Value 69 15562 206115_at EGR3 early growth response 3 2,36 5,13 4,51E-06 56 41486 232231_at RUNX2 runt-related transcription factor 2 2,01 4,02 6,78E-07 41 36660 227404_s_at EGR1 early growth response 1 1,99 3,97 2,20E-04 396 54249 36711_at MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F 1,92 3,79 7,54E-04 (avian) 42 13670 204222_s_at GLIPR1 GLI pathogenesis-related 1 (glioma) 1,91 3,76 2,20E-04 65 11080 201631_s_at IER3 immediate early response 3 1,81 3,50 3,50E-06 101 36952 227697_at SOCS3 suppressor of cytokine signaling 3 1,76 3,38 4,71E-05 16 15514 206067_s_at WT1 Wilms tumor 1 1,74 3,34 1,87E-04 171 47873 238623_at NA NA 1,72 3,30 1,10E-04 600 14687 205239_at AREG amphiregulin (schwannoma-derived growth factor) 1,71 3,26 1,51E-03 256 36997 227742_at CLIC6 chloride intracellular channel 6 1,69 3,23 3,52E-04 14 15038 205590_at RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 1,68 3,20 1,87E-04 55 33237 223961_s_at CISH cytokine inducible SH2-containing protein 1,67 3,19 6,49E-07 78 32152 222872_x_at OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A 1,66 3,15 1,23E-05 1969 32201 222921_s_at HEY2 hairy/enhancer-of-split related with YRPW motif 2 1,64 3,12 1,78E-02 122 13463 204015_s_at DUSP4 dual specificity phosphatase 4 1,61 3,06 5,97E-05 173 36466 227210_at NA NA 1,60 3,04 1,10E-04 117 40525 231270_at CA13 carbonic anhydrase XIII 1,59 3,02 5,62E-05 81 42339 233085_s_at OBFC2A oligonucleotide/oligosaccharide-binding
    [Show full text]